Clinical and Immunological Features of Human BCL10 Deficiency
Blanca García‐Solis, Ana Van Den Rym, Jareb J. Pérez-Caraballo, Abdulwahab Al–Ayoubi, Anas M. Alazami, Lazaro Lorenzo, Carolina Cubillos‐Zapata, Eduardo López‐Collazo, Antonio Pérez‐Martínez, Luís M. Allende, Janet Markle, Miguel Fernández‐Arquero, Silvia Sánchez‐Ramón, María J. Recio, Jean‐Laurent Casanova, Reem Mohammed, Rubén Martínez‐Barricarte, Rebeca Pérez de Diego
Abstract
The CARD-BCL10-MALT1 (CBM) complex is critical for the proper assembly of human immune responses. The clinical and immunological consequences of deficiencies in some of its components such as CARD9, CARD11, and MALT1 have been elucidated in detail. However, the scarcity of BCL10 deficient patients has prevented gaining detailed knowledge about this genetic disease. Only two patients with BCL10 deficiency have been reported to date. Here we provide an in-depth description of an additional patient with autosomal recessive complete BCL10 deficiency caused by a nonsense mutation that leads to a loss of expression (K63X). Using mass cytometry coupled with unsupervised clustering and machine learning computational methods, we obtained a thorough characterization of the consequences of BCL10 deficiency in different populations of leukocytes. We showed that in addition to the near absence of memory B and T cells previously reported, this patient displays a reduction in NK, γδT, Tregs, and T FH cells. The patient had recurrent respiratory infections since early childhood, and showed a family history of lethal severe infectious diseases. Fortunately, hematopoietic stem-cell transplantation (HSCT) cured her. Overall, this report highlights the importance of early genetic diagnosis for the management of BCL10 deficient patients and HSCT as the recommended treatment to cure this disease.